In neurological disorders, mogroside V demonstrates antidepressant effects in CUMS-induced depressive mice by modulating inflammatory/oxidative stress pathways and the brain-derived neurotrophic factor (BDNF)/tropomyosin receptor kinase B (TrkB)/protein kinase B (AKT) cascade, while also ameliorating schizophrenia-like behaviors in MK801-treated models (Liu et al., 2023, Ju et al., 2020). This evidence concerns the gene AKT1 and nervous system disorder.